LT3458045T - Ebselenas, skirtas naudoti menjero ligos gydymui - Google Patents

Ebselenas, skirtas naudoti menjero ligos gydymui

Info

Publication number
LT3458045T
LT3458045T LTEPPCT/US2017/033379T LTUS2017033379T LT3458045T LT 3458045 T LT3458045 T LT 3458045T LT US2017033379 T LTUS2017033379 T LT US2017033379T LT 3458045 T LT3458045 T LT 3458045T
Authority
LT
Lithuania
Prior art keywords
méniere
ebselen
disease
treatment
Prior art date
Application number
LTEPPCT/US2017/033379T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jonathan Kil
Original Assignee
Sound Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Incorporated filed Critical Sound Pharmaceuticals Incorporated
Publication of LT3458045T publication Critical patent/LT3458045T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LTEPPCT/US2017/033379T 2016-05-18 2017-05-18 Ebselenas, skirtas naudoti menjero ligos gydymui LT3458045T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662338443P 2016-05-18 2016-05-18
PCT/US2017/033379 WO2017201318A1 (en) 2016-05-18 2017-05-18 Treatment of meniere's disease

Publications (1)

Publication Number Publication Date
LT3458045T true LT3458045T (lt) 2024-12-10

Family

ID=60326098

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/033379T LT3458045T (lt) 2016-05-18 2017-05-18 Ebselenas, skirtas naudoti menjero ligos gydymui

Country Status (20)

Country Link
US (2) US12427138B2 (enExample)
EP (2) EP3458045B1 (enExample)
JP (1) JP7100866B2 (enExample)
KR (1) KR102474830B1 (enExample)
CN (2) CN122516370A (enExample)
AU (1) AU2017267732B2 (enExample)
CA (1) CA3026007A1 (enExample)
CY (1) CY1127309T1 (enExample)
DK (1) DK3458045T3 (enExample)
ES (1) ES2990157T3 (enExample)
FI (1) FI3458045T3 (enExample)
HR (1) HRP20241559T1 (enExample)
HU (1) HUE069280T2 (enExample)
LT (1) LT3458045T (enExample)
PL (1) PL3458045T3 (enExample)
PT (1) PT3458045T (enExample)
RS (1) RS66167B1 (enExample)
SI (1) SI3458045T1 (enExample)
SM (1) SMT202400469T1 (enExample)
WO (1) WO2017201318A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102981462B1 (ko) 2020-02-24 2026-06-23 상하이테크 유니버시티 N-치환 피리딜벤즈이소셀레나졸론 화합물의 용도
CN113288895B (zh) * 2021-06-21 2026-06-23 北华大学 一种用于治疗梅尼埃症的药物及其应用
JP2025504263A (ja) * 2021-12-23 2025-02-10 ユニバーシティ オブ ロチェスター 内耳への薬剤の送達のためのcsf輸送経路
WO2023240092A1 (en) 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Ebselen containing oral dosage forms
EP4536192A1 (en) 2022-06-06 2025-04-16 Sound Pharmaceuticals Incorporated Amorphous dosage form containing ebselen
WO2026073143A1 (en) * 2024-09-27 2026-04-02 Sound Pharmaceuticals Inc. Cochlear implant eluting ebselen for treating hearing loss

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3827093A1 (de) 1988-08-10 1990-02-15 Nattermann A & Cie Verfahren zur herstellung von hochreinem ebselen
JPH02202818A (ja) 1988-12-09 1990-08-10 Allergan Inc 白内障の治療における2―置換―チアゾリジン―4―カルボン酸類の用途
DK1471902T3 (da) 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
US20070105782A1 (en) 2005-10-07 2007-05-10 Board Of Trustees Of Southern Illinois University Protectant Combinations for Reducing Toxicities
JP5236641B2 (ja) * 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
EP2310038A4 (en) * 2008-05-15 2012-03-14 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCE OF IMPROVENCE WITH COMPOUNDS WITH ERYTHROPOETIN EFFECT
CN106344495A (zh) 2008-12-22 2017-01-25 奥德纳米有限公司 用于治疗耳部病症的控制释放耳感觉细胞调节剂组合物
WO2012106654A1 (en) * 2011-02-04 2012-08-09 Hough Ear Institute Methods for treating brain injury
EP2736890A4 (en) 2011-07-28 2015-07-15 Promentis Pharm Inc Cysteine PRODRUGS
CN102526734A (zh) 2012-01-12 2012-07-04 王玉丰 治疗年龄相关性听力损失的药物组合物及其应用
US20150374779A1 (en) 2014-06-26 2015-12-31 Auris Medical Ag Pharmacologic treatments of meniére's disease
AU2015317877A1 (en) 2014-09-15 2017-05-04 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
EP3478269A4 (en) 2016-06-29 2020-04-08 Otonomy, Inc. OTIC FORMULATIONS BASED ON TRIGLYCERIDES AND THEIR USES
US10750005B2 (en) 2018-09-27 2020-08-18 International Business Machines Corporation Selective email narration system

Also Published As

Publication number Publication date
CN122516370A (zh) 2026-08-07
CY1127309T1 (el) 2026-02-25
CN109475518A (zh) 2019-03-15
PT3458045T (pt) 2024-10-28
KR20190043499A (ko) 2019-04-26
DK3458045T3 (da) 2024-11-04
EP4461360A2 (en) 2024-11-13
RS66167B1 (sr) 2024-12-31
EP4461360A3 (en) 2025-01-22
HUE069280T2 (hu) 2025-02-28
EP3458045A4 (en) 2020-09-16
JP7100866B2 (ja) 2022-07-14
SMT202400469T1 (it) 2025-01-14
ES2990157T3 (es) 2024-11-29
FI3458045T3 (fi) 2024-10-24
CN109475518B (zh) 2026-05-08
EP3458045B1 (en) 2024-08-21
PL3458045T3 (pl) 2025-01-07
JP2019516727A (ja) 2019-06-20
US20200261417A1 (en) 2020-08-20
US12427138B2 (en) 2025-09-30
KR102474830B1 (ko) 2022-12-06
SI3458045T1 (sl) 2025-03-31
EP3458045A1 (en) 2019-03-27
AU2017267732A1 (en) 2018-12-20
US20260166010A1 (en) 2026-06-18
CA3026007A1 (en) 2017-11-23
HRP20241559T1 (hr) 2025-02-14
WO2017201318A1 (en) 2017-11-23
AU2017267732B2 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
SI3672954T1 (sl) Spojine, njihove soli in njihova uporaba za zdravljenje bolezni
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep
DK3364997T5 (da) Aspartoacylase genterapi til behandling af canavans sygdom
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
HUE071155T2 (hu) Biszkolin-tetratiomolibdát Wilson-kór kezelésére
HUE063369T2 (hu) Vegyületek Alzheimer-kór kezelésében történõ alkalmazásra APOE4+/+ betegekben
IL263433A (en) Methods for treating alzheimer's disease
HRP20181490T1 (hr) Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka
DK3463351T3 (da) Behandling til parkinsons sygdom
LT3592355T (lt) Kx2-391/kx-01, skirtas naudoti aktininės keratozės gydymui
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
DK3452465T3 (da) Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
IL262902A (en) Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
LT3609486T (lt) Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui
PL3148588T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia choroby parkinsona
PL3302463T3 (pl) Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu
DK3423081T3 (da) Sammensætninger til brug i behandlingen af neurologisk sygdom
PT3397273T (pt) Alfa-glicosidase ácida aumentada para o tratamento da doença de pompe